November
Clinical Operations
Strategy Meeting East Coast USA 2023
New Discoveries in Technology to Enhance Remote & Virtual Approaches, Utilisation of Telemedicine To Optimise Your Clinical Operation Success
What makes our strategy meetings unique?

Roundtable Discussions
Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking
With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda
Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems
We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics
We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers
The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.
Meet Our 2023 Facilitators
Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Clinical Operations strategy meeting.

Elina Lavit
Vice President of Business Development OncoNano Medicine
Emilio Neto
Head of US Clinical Country & Site Management, Senior Director Biogen
Eyal Ron
Executive Board Member and Co-Founder Keyron
Geraldine Briand Brucelle
Head of Clinical Study Operations Management & Academy Novartis Institutes for Biomedical Research (NIBR)
George Naumov
COO & CBO RS Oncology
Nelio Drumond
Associate Director – Global Manufacturing Sciences Takeda
Penny Carlson
Vice President, Head of Innovation & Data Takeda Pharmaceuticals
Siew Tin Gan
Head Of Clinical Operations Acumen Pharmaceuticals
Wasfi Alazzam
Director of Operations and Partnerships TakedaWho Should Attend the Event?
Clinical Operations
Clinical Project/ Program Leads
Clinical Quality Assurance
Clinical Research
Clinical Outsourcing
Data Management
Vendor Management
Medical/Scientific Officers
Biometrics
Medical Affairs
Patient affairs
Global study
Site management/ selection
Digital health
TMF/eTMF
Data monitoring
Patient recruitment
Patient engagement
Clinical investigation
Study optimisation
Patient insights
Clinical systems
See Which Topics Are Discussed at the Strategy Meeting
Roundtable Tracks
1Enhancing Trial Knowledge And Driving Better Outcomes By Using RBQM And Deep Learning (Topic TBC)
-Prajna Kumar
Vice President, Head of Clinical and Pharmacovigilance Quality
Blueprint Medicine
DECENTRALIZED/HYBRID TRIALS
Improving Digital Patient Recruitment For DCT’s To Enhance Diversity And Representation In Clinical Trials By Utilizing Digital Recruitment Techniques To Target Qualified Participants, While Also Taking Into Account Patient Population Demographics
EMERGING BIOPHARMA / OUTSOURCING
What future developments and commercial realities businesses with concentrated pipelines or single assets are facing?
-Elina Lavit
Vice President of Business Development
OncoNano Medicine
DIGITAL MEASUREMENTS/ CLINICAL DATA
Utilize And Support A More Digital Environment To Stay Relevant As The Industry Changes
GLOBAL SITE SELECTION AND FEASIBILITY STUDY
Building connections that ease site and sponsor load and enhance the patient experience
DIVERSITY, EQUITY, AND INCLUSION IN PATIENT EST ENGAGEMENT
Describing the tactics for promoting more community participation and enhancing clinical trial diversity
-Siew Tin Gan
Head Of Clinical Operations
Acumen Pharmaceuticals
Roundtable Tracks
2Making the Most of Your RBQM Solution Through the Establishment of Key Risk Indicators And Setting The Appropriate Thresholds (Topic TBC)
DECENTRALIZED/HYBRID TRIALS
Leveraging Site Selection for Clinical Trial Decentralization
EMERGING BIOPHARMA / OUTSOURCING
Building a foundation for future development and success by fostering a culture of innovation and compliance for an evolving organization (Topic TBC)
DIGITAL MEASUREMENTS/ CLINICAL DATA
Smart Signals/Devices To Capture Real-World Behavior, Gather Data More Often, And Run A Simulated Research While Remotely Monitoring Patient Safety (Topic TBC)
GLOBAL SITE SELECTION AND FEASIBILITY STUDY
Discover how a single sponsor/vendor partnership uses solution integration to address issues with technology platforms, burden for sites, invaluable applications of data, and inefficient change management procedures (Topic TBC)
DIVERSITY, EQUITY, AND INCLUSION IN PATIENT EST ENGAGEMENT
How Can We Recognize And Eliminate Obstacles That Prevent Minority Involvement, Such As Historical Distrust, Accessibility Issues, And A Lack of Awareness
Roundtable Tracks
3A Developed Risk-Based Quality Management Approach To Mitigate Potential Risks and Liabilities
-Penny Carlson
Vice President, Head of Innovation & Data
Takeda Pharmaceuticals
DECENTRALIZED/HYBRID TRIALS
Practical factors to take into account while switching to hybrid or decentralised clinical trials
EMERGING BIOPHARMA / OUTSOURCING
Building connections that ease site and sponsor load and enhance the patient experience
-George Naumov
COO & CBO
RS Oncology
DIGITAL MEASUREMENTS/ CLINICAL DATA
Discussing The Quality of Additional Data Resulting From New Approaches Used In Clinical Trials
GLOBAL SITE SELECTION AND FEASIBILITY STUDY
What are the biggest feasibility errors that even the most experienced sponsors occasionally make and how can we have a hands-on approach to avoid these mistakes?
-Emilio Neto
Head of US Clinical Country & Site Management, Senior Director
Biogen
DIVERSITY, EQUITY, AND INCLUSION IN PATIENT EST ENGAGEMENT
What obstacles do pharmaceutical and biotech businesses have to overcome in order to adequately represent various populations in clinical trials?
Roundtable Tracks
4A Developed Risk-Based Quality Management Approach To Mitigate Potential Risks and Liabilities
DECENTRALIZED/HYBRID TRIALS
How can we guarantee that the DCT’s many components use patient data in an effective and secure manner?
EMERGING BIOPHARMA / OUTSOURCING
What techniques can we employ to create a scalable culture in emerging biopharmaceutical companies?
DIGITAL MEASUREMENTS/ CLINICAL DATA
What strategies can we use to align digital transformation, and leverage data analytics in order to improve clinical trials and encourage growth?
GLOBAL SITE SELECTION AND FEASIBILITY STUDY
What tactics can we employ to successfully choose a site and do precise feasibility assessments?
DIVERSITY, EQUITY, AND INCLUSION IN PATIENT EST ENGAGEMENT
Tactics to promote change and inclusion in clinical research by using strategies that foster diversity in all elements and phases of clinical research
Roundtable Tracks
5Choosing The Best Monitoring Method To Improve Patient Compliance And Data Consistency – Centralized Monitoring vs Remote Monitoring
DECENTRALIZED/HYBRID TRIALS
Improving Retention: Supporting decentralized techniques that lessen patient burden and maintain patient engagement
EMERGING BIOPHARMA / OUTSOURCING
Discussing the challenges in limited resources, inadequate infrastructure, delays in manufacturing and clinical supply, and funding concerns emerging biopharma and biotechs face
-Eyal Ron
Executive Board Member and Co-Founder
Keyron
DIGITAL MEASUREMENTS/ CLINICAL DATA
How Can We Use Algorithms And Other Modern Methods To Clean And Interpret Data?
GLOBAL SITE SELECTION AND FEASIBILITY STUDY
Identifying Your Sites by Examining Selection Criteria and Site Performance: What Selection Criteria May Inhibit Your Clinical Trial’s Success?
DIVERSITY, EQUITY, AND INCLUSION IN PATIENT EST ENGAGEMENT
Eliminating Health Inequities: How can we improve the diverse representation of clinical trial programs to drive health equity?
Reasons To Attend the Strategy Meeting

Our unique closed door round-table discussion format is exclusively designed to engage 10-15 CxO, VP and director-level individuals from pharma, biotech and thought leaders from academia, to address and find solutions to industry challenges from a strategic perspective within the Clinical community





Bespoke networking opportunities to help streamline your procurementrnprocesses, meaning the impetus for your peers attending is solely based around making business decisions at the highest level





To gain practical insight with Good Clinical Practice and Risk Based QualityrnManagement strategies





Improve diversity through patient-centric approaches, decentralized trials and new digital technologies
Press play to hear what your colleagues had to say…


Hotel & Venue
Le Méridien Boston Cambridge
Posh hotel minutes from Harvard Square and Beacon Hill, steps from shopping, dining & entertainment.
Hotel Details Map & Directions Parking









Want to find out more?
Find out more details about our Strategy Meetings and other news and events.
Here To Help
Want to know more? Interested in sponsoring the event? Need help registering your team?rnrnJust get in touch and a member of the team will be happy to help.